• Medipost will hold a non-deal roadshow for domestic institutional investors in Seoul on Nov. 5-6, 2026.
• One-on-one, in-person meetings will cover Cartistem’s global clinical trial progress, commercialization strategy and partnerships.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medipost Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261103900437), on November 03, 2026, and is solely responsible for the information contained therein.